We are live on ! Find out more
OCUL icon

Ocular Therapeutix
OCUL

149 hedge funds and large institutions have $685M invested in Ocular Therapeutix in 2021 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 59 increasing their positions, 35 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more call options, than puts

Call options by funds: $24.5M | Put options by funds: $11.1M

69% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 35

1.29% more ownership

Funds ownership: 62.11% → 63.4% (+1.3%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

3% less funds holding

Funds holding: 154 → 149 (-5)

12% less capital invested

Capital invested by funds: $774M → $685M (-$89.5M)

18% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 28

Holders
149
Holders Change
-5
Holders Change %
-3.25%
% of All Funds
2.59%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
23
Increased
59
Reduced
35
Closed
28
Calls
$24.5M
Puts
$11.1M
Net Calls
+$13.3M
Net Calls Change
+$12.2M

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$27M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$15.4M
3
KCM
Kornitzer Capital Management
Kansas
+$8.53M
4
AS
Altshuler Shaham
Israel
+$8.22M
5
Renaissance Technologies
Renaissance Technologies
New York
+$4.21M

Top Sellers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
-$23.4M
2
BlackRock
BlackRock
New York
-$13.5M
3
CM
Castleark Management
Illinois
-$7.97M
4
Wells Fargo
Wells Fargo
California
-$7.04M
5
Federated Hermes
Federated Hermes
Pennsylvania
-$5.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
101
Millennium Management
New York
$215K -$2.72M -179,151 -92%
AB
102
Amalgamated Bank
New York
$205K +$63.9K +4,203 +41%
EGM
103
Engineers Gate Manager
New York
$196K -$89.8K -5,909 -30%
NA
104
NewEdge Advisors
Louisiana
$195K – – –
GSEP
105
Golden State Equity Partners
California
$190K +$204K +13,400 New
TC
106
TwinBeech Capital
New York
$189K +$202K +13,311 New
Marshall Wace
107
Marshall Wace
United Kingdom
$186K +$199K +13,114 New
Rafferty Asset Management
108
Rafferty Asset Management
New York
$182K +$196K +12,863 New
VF
109
Virtu Financial
New York
$179K -$50.1K -3,297 -21%
CIBC Private Wealth Group
110
CIBC Private Wealth Group
Georgia
$171K – – –
BIAS
111
Beacon Investment Advisory Services
New Jersey
$170K – – –
Ameriprise
112
Ameriprise
Minnesota
$162K +$1.87K +123 +1%
Victory Capital Management
113
Victory Capital Management
Texas
$159K -$23.4M -1,537,447 -99%
Zurich Cantonal Bank
114
Zurich Cantonal Bank
Switzerland
$155K +$3.85K +253 +2%
HighTower Advisors
115
HighTower Advisors
Illinois
$146K -$15.4K -1,016 -9%
ECM
116
ExodusPoint Capital Management
New York
$143K +$154K +10,101 New
TRCT
117
Tower Research Capital (TRC)
New York
$118K +$61.3K +4,031 +95%
LC
118
Lindbrook Capital
California
$116K +$15.2K +1,000 +14%
SAM
119
Shell Asset Management
Netherlands
$103K – – –
Ensign Peak Advisors
120
Ensign Peak Advisors
Utah
$85K -$816K -53,711 -90%
AIP
121
Ameritas Investment Partners
Nebraska
$81K – – –
Walleye Trading
122
Walleye Trading
New York
$80K +$86K +5,657 New
ACA
123
Atlas Capital Advisors
Wyoming
$70.9K – – –
OSAM
124
O'Shaughnessy Asset Management
Connecticut
$58K – – –
Canada Life
125
Canada Life
Manitoba, Canada
$57K – – –
3 4
5
6 7

OCUL Hedge Fund Activity: Q2 2021 in Review

149 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q2 2021, worth a combined $685M — down 12% from $774M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of OCUL and 23 opened new positions — a net loss of 5 holders — while 35 trimmed existing stakes and 59 added.

The largest buyer was Rubric Capital Management (New York), adding an estimated $27M. The largest seller was Victory Capital Management, cutting an estimated $23.4M.

  • 149 institutional investors held Ocular Therapeutix (OCUL) as of Q2 2021, down from 154 in Q1 2021.
  • Funds reported $685M of Ocular Therapeutix stock for Q2 2021, down 12% quarter-over-quarter.
  • 23 funds opened new Ocular Therapeutix positions in Q2 2021 and 28 closed out, a net change of -5 holders.
  • The largest Ocular Therapeutix buyer in Q2 2021 was Rubric Capital Management (New York), an estimated $27M added.
  • The largest Ocular Therapeutix seller in Q2 2021 was Victory Capital Management, an estimated $23.4M sold.

Based on aggregated 13F filings for Q2 2021.